Last reviewed · How we verify

Sulphadoxine-pyrimethamine with amodiaquine

London School of Hygiene and Tropical Medicine · Phase 2 active Small molecule

Sulphadoxine-pyrimethamine with amodiaquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development. Also known as: Supyra.

At a glance

Generic nameSulphadoxine-pyrimethamine with amodiaquine
Also known asSupyra
SponsorLondon School of Hygiene and Tropical Medicine
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sulphadoxine-pyrimethamine with amodiaquine

What is Sulphadoxine-pyrimethamine with amodiaquine?

Sulphadoxine-pyrimethamine with amodiaquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.

Who makes Sulphadoxine-pyrimethamine with amodiaquine?

Sulphadoxine-pyrimethamine with amodiaquine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is Sulphadoxine-pyrimethamine with amodiaquine also known as anything else?

Sulphadoxine-pyrimethamine with amodiaquine is also known as Supyra.

What development phase is Sulphadoxine-pyrimethamine with amodiaquine in?

Sulphadoxine-pyrimethamine with amodiaquine is in Phase 2.

Related